Skip to main content

Table 1 Comparison of characteristics before and after propensity score matching

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

Variables Before matching After matching
XELOX group
(n = 172)
DOS group
(n = 89)
P XELOX group
(n = 159)
DOS group
(n = 89)
P
Gender    0.130    0.224
 Male 131 (76.1) 60 (67.4)   120 (75.5) 60 (67.4)  
 Female 41 (23.9) 29 (32.6)   39 (24.5) 29 (32.6)  
Age (median year, range)    0.152    0.214
 Median 62 59   62 59  
 Range 31–78 24–74   31–78 24–74  
 60 101 (58.7) 44 (49.4)   93 (58.5) 44(51.2)  
Location    0.857    0.966
 Gastroesophageal junction 56 (32.5) 28 (31.5)   51 (32.1) 28 (31.5)  
 Stomach 116 (67.5) 61 (68.5)   108 (67.9) 61 (68.5)  
Lauren type    0.043    0.167
 Intestinal type 96 (55.8) 42 (47.2)   89 (55.9) 42 (47.2)  
 Diffuse type 48 (27.9) 38 (44.7)   49 (29.0) 38 (44.7)  
 Mixed type 28 (16.3) 9 (8.1)   21 (15.1) 9 (8.1)  
CEA    0.055    0.197
 Normal 133 (77.3) 59 (66.3)   119 (74.8) 59 (66.3)  
 Elevated 39 (22.7) 30 (33.7)   40 (25.2) 30 (33.7)  
Causes of unresection    0.493    0.454
 T4b 11 (6.4) 7 (7.8)   10 (6.3) 7 (7.8)  
 Borrmanntype 4 or large type 3 57 (33.1) 35 (39.3)   52 (32.7) 35 (39.3)  
 Bulky lymph nodes 104 (60.5) 47 (52.9)   97 (64.0) 47 (52.9)  
Clinical T stage    0.579    0.535
 cT3 9 (5.2) 7 (7.9)   8 (5.0) 7 (7.9)  
 cT4 163 (94.8) 82 (92.1)   151 (95.0) 82 (92.1)  
Clinical N stage    0.485    0.459
 cN1 56 (32.6) 32 (36.0)   52 (32.7) 32 (36.0)  
 cN2 73 (42.4) 31 (34.8)   68 (42.8) 31 (34.8)  
 cN3 43 (25.0) 26 (29.2)   39 (24.5) 26 (29.2)